DelveInsight Business Research LLP

DelveInsight’s ‘ICOS-Next Generation Immunotherapy Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the ICOS as well as the market trends of ICOS-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Highlights for ICOS Next Generation Immunotherapy

• The Key Companies working in the ICOS Next Generation Immunotherapy market is as follows Jounce Therapeutics, GlaxoSmithKline, Kymab, Bristol-Myers Squibb, Xencor, and many others.

• The Key Therapies working in the ICOS Next Generation Immunotherapy market is as follows GSK3359609, Vopratelimab, KY1044, and many others 

ICOS-Next Generation Immunotherapy Overview

Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the “fifth pillar” of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI that has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules.

Inducible co-stimulator (ICOS) is a specific T cell co-stimulatory molecule of the CD28/CTLA-4 family mainly expressed by CD4 T cells. It is a co-stimulator of proliferation and cytokine production by these cells. Its levels are upregulated in activated T lymphocytes, especially after the use of anti-CTLA4 therapies, and its expression is considered as a biomarker to indicate that anti-CTLA4 agents are binding its target.

Interestingly, ICOS appears to be a less potent pathway compared to other forms of immunotherapy mainly because of a predominant CD4 expression. However, its use with other approaches, particularly CTLA4 blockade can lead to a potent synergistic effect as a result of an increase in the expression of ICOS after anti-CTLA4 therapy.

The rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer.

Click here to learn more about the ICOS-Next Generation Immunotherapy Market Landscape

The Report Covers the ICOS-Next Generation Immunotherapy Epidemiology Segmented by:

• ICOS-Next Generation Immunotherapy  prevalent cases  

• ICOS-Next Generation Immunotherapy  incident cases 

• ICOS-Next Generation Immunotherapy  treatment cases 

• ICOS-Next Generation Immunotherapy  diagnosed cases 

ICOS-Next Generation Immunotherapy Market Outlook 

The ICOS-Next Generation Immunotherapy market outlook helps to cultivate a detailed comprehension of the historical, current, and forecasted market trends by analyzing the market, unmet needs, drivers and barriers, and demand for better technology. 

This segment gives a thorough detail of the ICOS-Next Generation Immunotherapy market trend of each late-stage pipeline therapy by evaluating their impact based on the annual cost of treatment, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear picture of the market at first sight.

According to DelveInsight, the ICOS-Next Generation Immunotherapy market is expected to generate USD 8,676 Million in the year 2035 with a significant CAGR in the forecast period (2022─2035).

Key Companies Working in the ICOS-Next Generation Immunotherapy Market

• Jounce Therapeutics, 

• GlaxoSmithKline, 

• Kymab,

• Bristol-Myers Squibb, 

• Xencor, 

And many others.

ICOS-Next Generation Immunotherapy Therapies Covered and Analyzed in the Report

• GSK3359609

• Vopratelimab

• KY1044

• BMS-98622

• XmAb23104

And many others 

Learn more about the Key Companies and Emerging Therapies in the ICOS-Next Generation Immunotherapy Market

Table of Contents 

1.  Key Insights 

2.  ICOS-Next Generation Immunotherapy  Introduction 

3.  Executive Summary of ICOS-Next Generation Immunotherapy            

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  ICOS-Next Generation Immunotherapy   Emerging Therapies

7.  ICOS-Next Generation Immunotherapy   Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ ICOS-Next Generation Immunotherapy  Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services